Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Last trade$9.88
Day change-$0.61 (-5.82%)
Day range$9.76 – $10.76
Volume586,758
Market cap$1.35B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.35B
Price / earnings
—
Price / book
3.55×
Price / sales
76.26×
EV / sales
69.39×
EV / EBITDA
-5.68×
Profitability
Earnings per share
-$1.74
Return on assets
-43.44%
Return on equity
-58.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.05×
Current ratio
5.01×
Quick ratio
5.01×
Cash ratio
1.7×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$248.72M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GENB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$4.22M
$6.31M
$7.22M
Cost of revenue
$0
$0
$0
Gross profit
$4.22M
$6.31M
$7.22M
Selling, general and administrative
$13.47M
$13.6M
$13.52M
Research and development
$82.25M
$64.33M
$57.81M
Total operating expenses
$95.73M
$77.93M
$71.34M
Operating income
-$91.51M
-$71.61M
-$64.11M
Interest expense
-$192K
-$155K
-$182K
Income before taxes
-$87.61M
-$67.2M
-$61.69M
Income taxes
$49K
$53K
$28K
Net income
-$87.66M
-$67.26M
-$61.71M
Net income attributable to common shareholders
-$87.66M
-$67.26M
-$69.2M
EBITDA
-$87.81M
-$68.39M
-$60.84M
Basic earnings per share
-$0.68
-$0.52
-$1.07
Diluted earnings per share
-$0.68
-$0.52
-$1.07
Recent news
Company coverage with links to the original publishers.
Global cancer research is advancing through AI-supported precision medicine, biomarker-guided treatments, and innovative approaches. Anthropic is supporting pediatric cancer care through the PCX program, while companies like AstraZeneca report survival improvements in gastric cancer with sonesitatug vedotin. Researchers in Japan and South Korea are exploring novel approaches including using cancer cells' own chemistry to produce treatments and reprogramming cancer cells toward normal states.
The global pharmaceutical market is projected to grow from USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035 at a 6.15% CAGR. India's pharmaceutical market recorded 17.1% year-over-year growth in September 2026. Key growth drivers include biologics, AI-driven drug discovery, specialty medicines, and manufacturing investments. Asia Pacific is expected to grow faster than the global average at 7.02% CAGR, while North America maintains 36% market share.
Cathie Wood's Ark Invest expanded positions in three recently-IPO'd stocks on Monday: Space Exploration Technologies (SpaceX), Generate Biomedicines, and Bullish. SpaceX, trading 19% above its IPO price, joins the Nasdaq-100 on Tuesday which should drive passive buying. Generate Biomedicines, a clinical-stage biotech company with AI-driven drug discovery, is trading above its February IPO price. Bullish, a crypto exchange and media company, has plummeted 72% since going public due to crypto market weakness.
Nvidia's venture capital arm has invested $13 million in Generate Biomedicines, a biotech company developing an AI platform for virtual drug testing. The platform addresses major pharmaceutical industry challenges by reducing development time and costs, with AI-discovered drugs showing twice the success rate in phase 1 trials. This investment signals Nvidia's confidence in the company's potential to transform the $1.8 trillion pharmaceutical market.
Nvidia's Q1 2026 13F filing reveals strategic investments in semiconductor and cloud companies, though some announced investments don't appear due to different security structures. The company significantly increased its CoreWeave holdings to $3.657 billion (95% increase in shares), made equal $2 billion investments in both CoreWeave and Nebius, and invested in Coherent for optical networking. Nvidia also made a small $10.4 million biotech investment in Generate Biomedicines.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.